Pharmaceutical combination comprising a CIP2A silencing agent for use in the treatment of a hyperproliferative disorder, preferably one with impaired p53 function

摘要

The invention is based on a finding that silencing CIP2A (KI-AA1524) gene sensitizes cancer cells for apoptosis-inducing activity of certain small molecule chemotherapeutic agents. Thus, the invention is directed to a respective combination therapy, sensitization method and pharmaceutical compositions. The invention further relates to a method of selecting cancer therapy for a subject on the basis of CIP2A and p53 expression and/or protein activity in a sample obtained from said subject.

主权项

1. A composition comprising a combination of:
at least one type of a CIP2A silencing agent selected from the group consisting of an siRNA molecule having at least 80% sequence identity to a sequence selected from SEQ ID NOS: 1-5 and having CIP2A silencing activity, and an shRNA molecule having at least 80% sequence identity to a sequence selected from SEQ ID NOS: 10-13 and 19 and having CIP2A silencing activity; at least one compound selected from the group consisting of PKC-412, PARP inhibitor III, indol-3-carbinol, cisplatin, rapamycin, TGX-221, NU-7441, S31-201, and gemcitabine; and at least one pharmaceutically acceptable carrier.